Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02127710 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
A Phase 2 study of Papillary Renal Cell Cancer, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
- 20
- Study locations
NCT02127710 is a Phase 2 study of Papillary Renal Cell Cancer that has completed, run by AstraZeneca. The registered enrollment target is 111 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT02127710, a Phase 2 study of Papillary Renal Cell Cancer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated. An independent central pathology review of tumour samples will be used to confirm the diagnosis of PRCC of all patients enrolling. However, locally available pathology results confirming PRCC will be allowed for timely study entry.
Conditions Studied
Interventions
- DRUG AZD6094
Study Locations (20)
Other
- Research Site - Barcelona
- Research Site - Cambridge
- Research Site - Glasgow
California
- Research Site - Duarte
- Research Site - Palo Alto
Texas
- Research Site - Dallas
- Research Site - Houston
Alberta
- Research Site - Calgary
- Research Site - Edmonton
Ontario
- Research Site - Toronto
- Research Site - Toronto
Alabama
- Research Site - Birmingham
Florida
- Research Site - Fort Myers
Illinois
- Research Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-04-30 |
| Est. Completion | 2020-04-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02127710
The ClinicalTrials.gov registry entry for NCT02127710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papillary Renal Cell Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD6094 is the first listed.
NCT02127710 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT02127710 about?
NCT02127710 is a clinical study titled "A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)". This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated. An independent central pathology review of tumour samples will be used...
What is the current status of trial NCT02127710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2014-04-30. Estimated completion is 2020-04-20.
What conditions does trial NCT02127710 study?
This clinical trial studies the following conditions: Papillary Renal Cell Cancer.
What interventions are being tested in trial NCT02127710?
The interventions under investigation include: AZD6094 (DRUG).
Who is sponsoring clinical trial NCT02127710?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02127710 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.